patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_385046 | REC_0003601 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 6.3 | 64 | male | 0 | 12 | 6.4 | 7 | sotorasib 960 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:57.734898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518009 | REC_0003602 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.8 | 63 | male | 1 | 21 | 7 | 6 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:57.735183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_175384 | REC_0003603 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 6.5 | 69 | female | 1 | 10 | 5 | 6 | pembrolizumab 200 mg q3w | 8.5 | true | MSS | 2026-03-15T05:35:57.735419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272946 | REC_0003604 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.4 | 53 | male | 0 | 18 | 2.9 | 7 | osimertinib 80 mg daily | 15 | false | MSI-H | 2026-03-15T05:35:57.735655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_103329 | REC_0003605 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13 | 67 | female | 0 | 19 | 5.8 | 6 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:57.735888+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553299 | REC_0003606 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14.7 | 59 | female | 1 | 9 | 6.7 | 1 | osimertinib 80 mg daily | 28 | false | MSS | 2026-03-15T05:35:57.736233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334859 | REC_0003607 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 16.3 | 56 | male | 0 | 15 | 6 | 2 | sotorasib 960 mg daily | 19.7 | false | MSI-H | 2026-03-15T05:35:57.736494+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_415795 | REC_0003608 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11.3 | 55 | female | 0 | 12 | 5.9 | 5 | sotorasib 960 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:57.736736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312740 | REC_0003609 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 16.4 | 58 | male | 1 | 16 | 6.2 | 6 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.736976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223527 | REC_0003610 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 35 | 11.1 | 68 | female | 0 | 21 | 6.8 | 0 | sotorasib 960 mg daily | 49.7 | true | MSS | 2026-03-15T05:35:57.737207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_218637 | REC_0003611 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 7.2 | 72 | male | 1 | 15 | 3 | 7 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:35:57.737442+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391920 | REC_0003612 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 25 | 12 | 75 | female | 2 | 17 | 8.1 | 0 | entrectinib 600 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:57.737670+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458712 | REC_0003613 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 8.2 | 60 | male | 1 | 32 | 5.3 | 2 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:35:57.737905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663938 | REC_0003614 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 11.2 | 61 | male | 0 | 24 | 4.8 | 1 | sotorasib 960 mg daily | 20.2 | false | MSI-H | 2026-03-15T05:35:57.738138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790630 | REC_0003615 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 11 | 74 | female | 2 | 10 | 5.3 | 4 | alectinib 600 mg BID | 10.5 | false | MSS | 2026-03-15T05:35:57.738429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564684 | REC_0003616 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.8 | 45 | male | 0 | 6 | 3.5 | 1 | pembrolizumab 200 mg q3w | 13.3 | false | MSS | 2026-03-15T05:35:57.738665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863561 | REC_0003617 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.6 | 63 | female | 0 | 28 | 3.2 | 1 | sotorasib 960 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:57.738902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964885 | REC_0003618 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 18 | 5.8 | 71 | female | 1 | 33 | 6.6 | 0 | carboplatin + paclitaxel + pembrolizumab | 41.4 | true | MSS | 2026-03-15T05:35:57.739138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_826202 | REC_0003619 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 8.7 | 75 | female | 1 | 14 | 5.8 | 5 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:57.739374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_640346 | REC_0003620 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.4 | 49 | male | 0 | 13 | 4.9 | 5 | osimertinib 80 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:57.739614+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933617 | REC_0003621 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.3 | 69 | female | 1 | 11 | 5 | 4 | sotorasib 960 mg daily | 14.5 | true | MSS | 2026-03-15T05:35:57.739859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127400 | REC_0003622 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 9.2 | 71 | male | 1 | 16 | 6.1 | 6 | osimertinib 80 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:57.740156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877524 | REC_0003623 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7.2 | 63 | male | 0 | 75 | 6 | 5 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:57.740417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963668 | REC_0003624 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 15.4 | 70 | female | 2 | 33 | 7.2 | 2 | entrectinib 600 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:57.740663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466511 | REC_0003625 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 15 | 7.1 | 65 | female | 0 | 14 | 4 | 2 | sotorasib 960 mg daily | 17 | false | MSS | 2026-03-15T05:35:57.740914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578298 | REC_0003626 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 6.5 | 70 | female | 2 | 20 | 5.7 | 5 | sotorasib 960 mg daily | 9.7 | false | MSS | 2026-03-15T05:35:57.741166+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334765 | REC_0003627 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 10 | 68 | female | 1 | 10 | 4.2 | 2 | entrectinib 600 mg daily | 8.8 | false | MSI-H | 2026-03-15T05:35:57.741424+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546543 | REC_0003628 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 4.9 | 52 | male | 0 | 20 | 5.9 | 5 | entrectinib 600 mg daily | 19.1 | false | MSS | 2026-03-15T05:35:57.741796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401391 | REC_0003629 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 16.5 | 76 | female | 1 | 16 | 7.8 | 3 | sotorasib 960 mg daily | 7.4 | false | MSI-H | 2026-03-15T05:35:57.742045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909347 | REC_0003630 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 2.2 | 66 | female | 0 | 32 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:35:57.742276+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298924 | REC_0003631 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.3 | 67 | female | 0 | 11 | 5.3 | 7 | alectinib 600 mg BID | 9 | true | MSI-H | 2026-03-15T05:35:57.742515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626302 | REC_0003632 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 4.8 | 69 | female | 0 | 34 | 4.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:57.742752+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_792661 | REC_0003633 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.2 | 69 | male | 0 | 0 | 6.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 10.2 | true | MSS | 2026-03-15T05:35:57.742987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386047 | REC_0003634 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 17 | 7.1 | 51 | female | 0 | 59 | 5.7 | 5 | pembrolizumab 200 mg q3w | 5.6 | true | MSS | 2026-03-15T05:35:57.743217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124202 | REC_0003635 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 9.4 | 80 | male | 1 | 13 | 6.5 | 2 | alectinib 600 mg BID | 18.2 | false | MSS | 2026-03-15T05:35:57.743450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356076 | REC_0003636 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 37 | 12.3 | 62 | female | 1 | 25 | 4.7 | 1 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:57.743686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610582 | REC_0003637 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 23 | 9.6 | 61 | male | 0 | 10 | 6.1 | 0 | osimertinib 80 mg daily | 29.1 | true | MSS | 2026-03-15T05:35:57.743925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339940 | REC_0003638 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 8.8 | 87 | male | 1 | 8 | 4.6 | 7 | sotorasib 960 mg daily | 11.1 | false | MSS | 2026-03-15T05:35:57.744211+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_838899 | REC_0003639 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 12.4 | 71 | female | 1 | 8 | 3.7 | 5 | osimertinib 80 mg daily | 17.7 | true | MSI-H | 2026-03-15T05:35:57.744453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_449192 | REC_0003640 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.7 | 55 | male | 1 | 3 | 6.4 | 1 | osimertinib 80 mg daily | 18.4 | false | MSS | 2026-03-15T05:35:57.744688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801927 | REC_0003641 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 7.4 | 72 | female | 0 | 10 | 6.5 | 6 | entrectinib 600 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:57.744994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808344 | REC_0003642 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 20 | 7.7 | 54 | female | 0 | 21 | 6.4 | 2 | pembrolizumab 200 mg q3w | 17.2 | true | MSS | 2026-03-15T05:35:57.745234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998892 | REC_0003643 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.9 | 72 | female | 1 | 13 | 5.6 | 5 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:57.745471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750359 | REC_0003644 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 10.6 | 65 | female | 1 | 7 | 5.1 | 2 | sotorasib 960 mg daily | 20.4 | true | MSS | 2026-03-15T05:35:57.745706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113977 | REC_0003645 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 11.7 | 64 | male | 2 | 18 | 6.1 | 6 | entrectinib 600 mg daily | 19.3 | true | MSI-H | 2026-03-15T05:35:57.745941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880274 | REC_0003646 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 28 | 16.8 | 64 | male | 0 | 21 | 5.5 | 0 | osimertinib 80 mg daily | 31.9 | false | MSS | 2026-03-15T05:35:57.746176+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_701081 | REC_0003647 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 9.2 | 78 | female | 1 | 51 | 4.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSS | 2026-03-15T05:35:57.746406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113018 | REC_0003648 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.9 | 75 | female | 2 | 19 | 6 | 1 | osimertinib 80 mg daily | 14.5 | false | MSS | 2026-03-15T05:35:57.746637+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_491494 | REC_0003649 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.6 | 64 | female | 1 | 5 | 5.8 | 2 | alectinib 600 mg BID | 17.7 | false | MSS | 2026-03-15T05:35:57.746872+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871980 | REC_0003650 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 33 | 14.7 | 63 | male | 0 | 19 | 4.7 | 6 | osimertinib 80 mg daily | 7 | false | MSS | 2026-03-15T05:35:57.747108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177742 | REC_0003651 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 12.6 | 61 | male | 1 | 1 | 8.2 | 1 | osimertinib 80 mg daily | 18.2 | false | MSI-H | 2026-03-15T05:35:57.747342+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_434375 | REC_0003652 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 14.7 | 74 | female | 2 | 10 | 5.8 | 7 | pembrolizumab 200 mg q3w | 18.9 | false | MSS | 2026-03-15T05:35:57.747572+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377111 | REC_0003653 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.9 | 73 | female | 1 | 54 | 6.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:35:57.747800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993354 | REC_0003654 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 16.9 | 82 | female | 0 | 15 | 5.1 | 6 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:57.748145+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926788 | REC_0003655 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12 | 62 | male | 0 | 26 | 5 | 6 | alectinib 600 mg BID | 16.7 | false | MSI-H | 2026-03-15T05:35:57.748396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_651143 | REC_0003656 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 10.6 | 66 | female | 1 | 20 | 6 | 1 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:57.748640+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287365 | REC_0003657 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.6 | 76 | female | 1 | 19 | 4.4 | 3 | alectinib 600 mg BID | 13.4 | true | MSI-H | 2026-03-15T05:35:57.748874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886377 | REC_0003658 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 33 | 14.8 | 46 | male | 0 | 7 | 5.5 | 7 | osimertinib 80 mg daily | 14.4 | true | MSI-H | 2026-03-15T05:35:57.749109+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_338073 | REC_0003659 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 6.7 | 62 | male | 0 | 5 | 5.7 | 2 | sotorasib 960 mg daily | 15.7 | false | MSS | 2026-03-15T05:35:57.749341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_973956 | REC_0003660 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 21.9 | 59 | female | 0 | 11 | 6.7 | 5 | entrectinib 600 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:35:57.749575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_228823 | REC_0003661 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 10.3 | 75 | male | 3 | 14 | 6.9 | 2 | sotorasib 960 mg daily | 20.3 | true | MSS | 2026-03-15T05:35:57.749811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_387319 | REC_0003662 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 9.8 | 59 | male | 0 | 5 | 4.9 | 2 | sotorasib 960 mg daily | 23 | true | MSS | 2026-03-15T05:35:57.750043+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865236 | REC_0003663 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.2 | 81 | female | 2 | 17 | 5.6 | 5 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:57.750275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957710 | REC_0003664 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 9.4 | 62 | female | 1 | 11 | 6.4 | 7 | alectinib 600 mg BID | 11 | false | MSS | 2026-03-15T05:35:57.750506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578372 | REC_0003665 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 4.4 | 68 | male | 1 | 46 | 7 | 3 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:57.750739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142432 | REC_0003666 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 28 | 9.7 | 56 | female | 1 | 11 | 6 | 2 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:35:57.750973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194055 | REC_0003667 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 7.2 | 76 | female | 0 | 21 | 3.6 | 3 | pembrolizumab 200 mg q3w | 10.9 | false | MSS | 2026-03-15T05:35:57.751256+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571518 | REC_0003668 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.7 | 67 | female | 1 | 19 | 6.3 | 2 | pembrolizumab 200 mg q3w | 18 | true | MSS | 2026-03-15T05:35:57.751492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718616 | REC_0003669 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.3 | 58 | female | 0 | 16 | 4.7 | 4 | entrectinib 600 mg daily | 8.7 | true | MSI-H | 2026-03-15T05:35:57.751727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376564 | REC_0003670 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.2 | 72 | female | 2 | 20 | 5.1 | 6 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:35:57.751963+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_484943 | REC_0003671 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 9.7 | 76 | male | 3 | 12 | 5.7 | 5 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:57.752302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324801 | REC_0003672 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.5 | 75 | female | 2 | 8 | 4.7 | 2 | osimertinib 80 mg daily | 24.9 | false | MSI-H | 2026-03-15T05:35:57.752545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_567114 | REC_0003673 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.3 | 86 | female | 2 | 18 | 4.4 | 5 | entrectinib 600 mg daily | 6.5 | false | MSI-H | 2026-03-15T05:35:57.752793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448813 | REC_0003674 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 14.7 | 83 | female | 1 | 17 | 5.2 | 6 | osimertinib 80 mg daily | 11.5 | false | MSS | 2026-03-15T05:35:57.753028+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897553 | REC_0003675 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 2.9 | 84 | female | 2 | 16 | 5.7 | 9 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:57.753259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227739 | REC_0003676 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 16.5 | 65 | female | 0 | 11 | 7.4 | 0 | entrectinib 600 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:57.753497+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_265451 | REC_0003677 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 16.8 | 78 | female | 2 | 17 | 5.1 | 5 | pembrolizumab 200 mg q3w | 16.2 | true | MSS | 2026-03-15T05:35:57.753730+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400358 | REC_0003678 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 5 | 65 | female | 0 | 27 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 16 | true | MSS | 2026-03-15T05:35:57.753964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_923120 | REC_0003679 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 19.4 | 74 | female | 3 | 23 | 5.4 | 1 | sotorasib 960 mg daily | 18.5 | false | MSS | 2026-03-15T05:35:57.754195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456831 | REC_0003680 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 15 | 60 | female | 0 | 22 | 4.5 | 1 | osimertinib 80 mg daily | 21.8 | true | MSI-H | 2026-03-15T05:35:57.754511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_361173 | REC_0003681 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 10.6 | 74 | female | 1 | 6 | 5.2 | 5 | alectinib 600 mg BID | 8.8 | false | MSS | 2026-03-15T05:35:57.754749+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287155 | REC_0003682 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 10.9 | 61 | female | 1 | 11 | 4.2 | 7 | osimertinib 80 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:57.754986+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451130 | REC_0003683 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 15.8 | 69 | female | 0 | 20 | 6.4 | 8 | sotorasib 960 mg daily | 21.4 | true | MSS | 2026-03-15T05:35:57.755223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_422698 | REC_0003684 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.7 | 63 | female | 0 | 61 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.8 | false | MSS | 2026-03-15T05:35:57.755454+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721804 | REC_0003685 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 9.2 | 68 | female | 1 | 18 | 4.7 | 8 | osimertinib 80 mg daily | 11.6 | true | MSS | 2026-03-15T05:35:57.755684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_384287 | REC_0003686 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 2.8 | 66 | female | 0 | 29 | 5.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.7 | true | MSS | 2026-03-15T05:35:57.755914+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322870 | REC_0003687 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.4 | 64 | male | 0 | 21 | 4.8 | 1 | osimertinib 80 mg daily | 18.7 | true | MSS | 2026-03-15T05:35:57.756264+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954558 | REC_0003688 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 6.8 | 75 | female | 2 | 11 | 7.9 | 7 | pembrolizumab 200 mg q3w | 10.6 | true | MSS | 2026-03-15T05:35:57.756500+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303184 | REC_0003689 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 17 | 14.7 | 71 | female | 1 | 2 | 4.8 | 7 | alectinib 600 mg BID | 10.5 | false | MSS | 2026-03-15T05:35:57.756739+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317903 | REC_0003690 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 6 | 66 | female | 1 | 10 | 4.5 | 5 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:57.756967+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_768651 | REC_0003691 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 11.6 | 72 | female | 1 | 17 | 7 | 3 | sotorasib 960 mg daily | 5.5 | true | MSS | 2026-03-15T05:35:57.757200+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_886214 | REC_0003692 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.4 | 71 | female | 0 | 35 | 7.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:57.757431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317025 | REC_0003693 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 16.1 | 62 | female | 0 | 10 | 3.1 | 7 | osimertinib 80 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:57.757748+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753561 | REC_0003694 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 12.8 | 74 | female | 2 | 6 | 8 | 1 | alectinib 600 mg BID | 19 | true | MSI-H | 2026-03-15T05:35:57.757984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556758 | REC_0003695 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 5.3 | 67 | male | 1 | 14 | 6.6 | 4 | alectinib 600 mg BID | 13.2 | true | MSS | 2026-03-15T05:35:57.758217+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393322 | REC_0003696 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.4 | 61 | male | 0 | 22 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:57.758448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874007 | REC_0003697 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.6 | 81 | female | 0 | 15 | 5.6 | 8 | alectinib 600 mg BID | 13 | true | MSS | 2026-03-15T05:35:57.758685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506334 | REC_0003698 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 14.7 | 79 | female | 1 | 14 | 5.2 | 5 | entrectinib 600 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:57.758937+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601186 | REC_0003699 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.5 | 75 | female | 1 | 26 | 3.8 | 6 | osimertinib 80 mg daily | 6.3 | false | MSI-H | 2026-03-15T05:35:57.759207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_346170 | REC_0003700 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12.6 | 63 | female | 0 | 21 | 6.1 | 5 | sotorasib 960 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:57.759480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.